Serotype distribution and antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates among adult and elderly population before and after introduction of pneumococcal conjugate vaccine in Casablanca, Morocco.
Adult population
Antibiotic resistance
Herd effect
Invasive pneumococcal diseases
Pneumococcal conjugate vaccine
Serotype
Streptococcus pneumoniae
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
13 Jan 2023
13 Jan 2023
Historique:
received:
15
09
2022
accepted:
02
01
2023
entrez:
13
1
2023
pubmed:
14
1
2023
medline:
18
1
2023
Statut:
epublish
Résumé
Streptococcus pneumoniae (S. pneumoniae), remains a major cause of mortality and morbidity worldwide. The objective of this study was to determine the trends of invasive pneumococcal diseases (IPD) in adult and elderly population in Casablanca (Morocco) before and after introduction of pneumococcal conjugate vaccine (PCV) by determining the distribution of pneumococcal serotypes and antibiotic resistance profile of isolated strains. The proposed study is a retrospective laboratory-based surveillance of IPD in hospitalized adult (15-59 years old) and elderly (≥ 60 years old) patients in Ibn Rochd University Hospital Centre from 2007 to 2019 (13 years). All the 250 non-duplicate clinical invasive isolates from adult and elderly patients, confirmed as S. pneumoniae according to the laboratory standard identification procedures, are included in this study. A significant decrease of the overall incidence in IPD was observed only in adults from 0.71 to 0.54/100000 populations (P = 0.02) and to 0.47/100000 populations (P = 0.0137) in the early and mature post-vaccine period respectively compared to the pre-vaccine period. Our results also showed a significant reduction in the overall prevalence of vaccine serotypes from 28.17 to 6.90% (P = 0.0021) for the PCV-10 serotypes, and from 46.48 to 25.86% (P = 0.0164) for the PCV-13 serotypes only in the mature post-vaccine period (2015-2019). In parallel, the rate of non-vaccine serotypes did not significantly change in the early post-vaccine period (2011-2014) while it increased considerably from 54 to 74.14% (P = 0.0189) during the mature post-vaccine period. The rate of penicillin non-susceptible pneumococcal isolates decreased significantly from 23.94 to 8.77% (P = 0.02) in adult patients, and the rate of cotrimoxazole non-susceptible pneumococcal isolates significantly decreased from 29.58 to 8.77% in the early post-vaccine period (P = 0.003) and to 7.24% in the mature post-vaccine period (P = 0.0007). Although childhood vaccination has considerably reduced the incidence of IPD in adult population through the herd effect, IPD remain a real public health problem due to the alarming increase in non-vaccine serotypes (NVS) and the lack of herd effect among elderly population. The rate of antibiotic resistance was relatively low. Nevertheless, resistance constitutes a serious problem to the therapeutic arsenal due to the known capacity for genetic dissemination in the pneumococcus.
Sections du résumé
BACKGROUND
BACKGROUND
Streptococcus pneumoniae (S. pneumoniae), remains a major cause of mortality and morbidity worldwide. The objective of this study was to determine the trends of invasive pneumococcal diseases (IPD) in adult and elderly population in Casablanca (Morocco) before and after introduction of pneumococcal conjugate vaccine (PCV) by determining the distribution of pneumococcal serotypes and antibiotic resistance profile of isolated strains.
METHOD
METHODS
The proposed study is a retrospective laboratory-based surveillance of IPD in hospitalized adult (15-59 years old) and elderly (≥ 60 years old) patients in Ibn Rochd University Hospital Centre from 2007 to 2019 (13 years). All the 250 non-duplicate clinical invasive isolates from adult and elderly patients, confirmed as S. pneumoniae according to the laboratory standard identification procedures, are included in this study.
RESULTS
RESULTS
A significant decrease of the overall incidence in IPD was observed only in adults from 0.71 to 0.54/100000 populations (P = 0.02) and to 0.47/100000 populations (P = 0.0137) in the early and mature post-vaccine period respectively compared to the pre-vaccine period. Our results also showed a significant reduction in the overall prevalence of vaccine serotypes from 28.17 to 6.90% (P = 0.0021) for the PCV-10 serotypes, and from 46.48 to 25.86% (P = 0.0164) for the PCV-13 serotypes only in the mature post-vaccine period (2015-2019). In parallel, the rate of non-vaccine serotypes did not significantly change in the early post-vaccine period (2011-2014) while it increased considerably from 54 to 74.14% (P = 0.0189) during the mature post-vaccine period. The rate of penicillin non-susceptible pneumococcal isolates decreased significantly from 23.94 to 8.77% (P = 0.02) in adult patients, and the rate of cotrimoxazole non-susceptible pneumococcal isolates significantly decreased from 29.58 to 8.77% in the early post-vaccine period (P = 0.003) and to 7.24% in the mature post-vaccine period (P = 0.0007).
CONCLUSION
CONCLUSIONS
Although childhood vaccination has considerably reduced the incidence of IPD in adult population through the herd effect, IPD remain a real public health problem due to the alarming increase in non-vaccine serotypes (NVS) and the lack of herd effect among elderly population. The rate of antibiotic resistance was relatively low. Nevertheless, resistance constitutes a serious problem to the therapeutic arsenal due to the known capacity for genetic dissemination in the pneumococcus.
Identifiants
pubmed: 36639755
doi: 10.1186/s12879-023-07981-y
pii: 10.1186/s12879-023-07981-y
pmc: PMC9838000
doi:
Substances chimiques
Vaccines, Conjugate
0
Pneumococcal Vaccines
0
Anti-Infective Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Informations de copyright
© 2023. The Author(s).
Références
Vaccine. 2013 Oct 1;31(42):4881-7
pubmed: 23928466
Infect Drug Resist. 2020 Feb 04;13:333-340
pubmed: 32099424
mBio. 2020 May 19;11(3):
pubmed: 32430472
EClinicalMedicine. 2019 Jan 02;6:42-50
pubmed: 31193709
Sci Rep. 2020 Nov 4;10(1):18977
pubmed: 33149149
PLoS Med. 2013;10(9):e1001517
pubmed: 24086113
Antibiotics (Basel). 2019 Apr 12;8(2):
pubmed: 31013803
Epidemiol Infect. 2017 Aug;145(11):2390-2399
pubmed: 28712384
Vaccine. 2012 Dec 31;30 Suppl 6:G46-50
pubmed: 23228358
Int J Infect Dis. 2019 Mar;80:129-133
pubmed: 30572022
Int J Infect Dis. 2015 Nov;40:95-101
pubmed: 26434380
N Engl J Med. 2014 Nov 13;371(20):1889-99
pubmed: 25386897
Thorax. 2019 May;74(5):473-482
pubmed: 30355641
Clin Microbiol Rev. 2015 Jul;28(3):871-99
pubmed: 26085553
Microb Drug Resist. 2012 Apr;18(2):157-60
pubmed: 22217142
J Infect Chemother. 2017 Apr;23(4):234-240
pubmed: 28161295
Front Microbiol. 2020 Oct 22;11:557404
pubmed: 33193140
PLoS One. 2019 Jan 10;14(1):e0210081
pubmed: 30629620
J Med Microbiol. 2017 Jul;66(7):847-858
pubmed: 28650313
Eur Respir J. 2016 Apr;47(4):1208-18
pubmed: 26797033
Hum Vaccin Immunother. 2018 Apr 3;14(4):1003-1012
pubmed: 29261406
BMC Genomics. 2021 Jan 7;22(1):39
pubmed: 33413118
Antimicrob Agents Chemother. 2001 Feb;45(2):627-9
pubmed: 11158769
Int J Infect Dis. 2017 Dec;65:110-115
pubmed: 29111412
Expert Rev Vaccines. 2019 Jun;18(6):641-661
pubmed: 31230486
Expert Rev Vaccines. 2018 Jun;17(6):479-493
pubmed: 29241390